ARTICLES BY CYNDI ROOT
NIH Resumes MERS, Flu Studies12/26/2014
The National Institutes of Health (NIH) has allowed studies for MERS (Middle East respiratory syndrome) and the flu top resume.
FDA Approves Teva’s QNASL For Pediatric Patients With Allergic Rhinitis12/26/2014
Teva Pharmaceutical has a new allergy treatment for children as young as four years old.
CRO KCR Acquires Clinical Portfolio From Ukrainian CRO AXIS12/22/2014
KCR, a contract research organization (CRO), has acquired the clinical portfolio of AXIS Group, a Ukrainian CRO.
Lightlake, Adapt Pharma Partner On Intranasal Naloxone Opioid Overdose Reversal Treatment12/18/2014
Lightlake Therapeutics and Adapt Pharma Operations have begun a partnership on Lightlake's intranasal naloxone opioid overdose reversal treatment.
Boehringer Ingelheim Enrolls Patients In Dabigatran Trial For Stroke12/17/2014
Boehringer Ingelheim has enrolled its first patient in a Phase 3 study of dabigatran etexilate (brand name Pradaxa) to prevent recurrent Embolic Stroke of Undetermined Source (ESUS).
US FDA, Taiwan FDA Approve TWi Biotechnology’s Phase 2 Gout Trial12/17/2014
TWi Pharmaceuticals is approved to run a Phase 2 trial of AC-201, according to the Food and Drug Administration (FDA) and the Taiwan FDA.
Lakewood-Amedex, Batu Biologics File Separate INDs With FD12/17/2014
Batu Biologics has filed for approval of a Phase 1/2 clinical trial for non-small cell lung cancer (NSCLC) while Lakewood-Amedex is planning to conduct a Phase 1/2a trial for diabetic foot infections.
La Jolla, George Washington University Partner On Angiotensin II For Hypotension, Shock12/16/2014
La Jolla Pharmaceutical Company and George Washington University (GW) have partnered to develop La Jolla’s angiotensin II products.
FDA Grants Orphan Status To Arca’s Ebola Treatment, Insys’ Gastric Cancer Treatment12/16/2014
The Food and Drug Administration (FDA) has granted Orphan Drug status to an Ebola treatment and a gastric cancer treatment.
FDA Approves Mast’s Study Of Vepoloxamer In Acute Decompensated Heart Failure12/15/2014
Mast Therapeutics announced its intentions to develop vepoloxamer (MST-188) in heart failure.